Suppression of bone loss by introducing FoxP3+ CD8 T-cells (TcREG)

Patent metadata

Field	Value
Publication number	US-9713633-B1
Application number	US-201615052793-A
Country	US
Kind code	B1
Filing date	Feb 24, 2016
Priority date	Feb 25, 2015
Publication date	Jul 25, 2017
Grant date	Jul 25, 2017

Abstract

Systems and methods for inhibiting bone loss using FoxP3+ CD8 T-cells (Tc REG ). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (Tc REG ) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

First claim

The invention claimed is:

1. A method for reducing bone loss in a patient, the method comprising:
providing said patient a RANK agonist being of:
sufficient amount to induce osteoclasts of said patient to produce FoxP3+ CD8 T-cells (Tc REG ); and
insufficient amount to activate enough of said osteoclasts to create bone loss in said patient;

repeating said providing according to a fixed schedule so as to provide said RANK agonist to said patient at pulsed intervals.

2. The method of claim 1 wherein said RANK agonist is RANKL.

3. The method of claim 1 wherein said low dose comprises 0.125 mg/kg RANKL or less.

4. The method of claim 1 wherein the pulsed intervals are about every 28 days.

Assignees

• Univ Saint Louis

Inventors

• Aurora Rajeev
• Buchwald Zachary

Classifications

• A61K38/177 Primary

  Receptors; Cell surface antigens; Cell surface determinants · CPC title